The global charcot marie tooth disease type 1 A drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. People with this disease experience weakness and wasting (atrophy) of the muscles of the lower legs beginning in adolescence; later they can also have hand weakness and sensory loss. While the involvement of the central nervous system in clinical phenotype of patients with charcot marie tooth disease has been reported in the past, its association with epilepsy has also been witnessed. A few patients with charcot marie tooth are reported to have epilepsy. According to the World Health Organization (WHO) epilepsy is a chronic non-communicable disease of the brain that affects people of all ages. As of 2019, nearly 50 million people across the globe had epilepsy. This makes epilepsy as one of the most common neurological diseases globally. 

Moreover, as per the WHO, it is also estimated that up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. The risk of premature mortalities in people with epilepsy is up to three times higher than for the general population. Although there is no complete cure discovered for charcot marie tooth disease, various researches investigating various pharmacological modulators of adenylyl cyclase activity, including ascorbic acid and ligands of G protein?coupled receptors (GPCRs), provide hope for future treatments of this type of hereditary motor and sensory neuropathy.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type 

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Sanofi S.A., and Addex Therapeutics, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Charcot Marie Tooth Disease Type 1 A Drug Market Report by Segment

By Product Type

• ADX-71441
• AFC-5128
• Others

By Application

• Hospital
• Clinic
• Others

Global Charcot Marie Tooth Disease Type 1 A Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa